Legend Biotech Corporation
LEGNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Legend Biotech Corporation focuses on Biotechnology services and products. Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other. Valued at $3.99B, LEGN is a mid-cap name in its sector. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Market Cap
$3.99B
Beta
0.40
P/E (TTM)
—
P/E (Fwd)
18.97
EPS (TTM)
$-0.50
EPS (Fwd)
$1.08
ROE
-8.1%
ROA
-1.9%
Cash
$964.6M
Total Debt
$278.2M
Free CF
$27.2M
52W Change
-35.7%
Annual Financials
Cash vs Debt
Where LEGN stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, LEGN finished 1.78% below its 150-day moving average ($23.01) and 4.88% below its 200-day moving average ($23.76). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LEGN overbought or oversold?
At the August 20, 2026 close, LEGN's RSI(14) was 72.2, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $964.6M in cash comfortably exceeding the $278.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $27.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -8.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $68.8M (2021) to $1.03B (2025), reflecting a 1395% increase over the period.
The relatively low beta of 0.40 suggests LEGN is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, LEGN has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LEGN.